<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39313888</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-3989</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Infectious disorders drug targets</Title><ISOAbbreviation>Infect Disord Drug Targets</ISOAbbreviation></Journal><ArticleTitle>The Relationship among SARS-CoV-2, Vaccine Spike Protein, Renin- Angiotensin System, and Epilepsy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/0118715265350339240919053408</ELocationID><Abstract><AbstractText>Several comorbidities and illnesses have emerged after the COVID-19 pandemic and the introduction of vaccination based on a slightly modified SARS-CoV-2 spike protein. One of these diseases is epilepsy, where the dysfunctional RAS plays a crucial role in the propagation of the disorder. SARS-CoV-2 infects host cells by utilizing the angiotensin-converting enzyme Type 2 (ACE2) receptor, which allows the virus to infect various cell types, including those in the lungs, nasopharynx, kidneys, lymph nodes, small intestine, stomach, spleen, and brain, leading to widespread organ damage. Once SARS-CoV-2 binds to the ACE2 receptor, it can lead to the overactivation of the ACE/Ang II/AT1R axis. Consequently, higher levels of Ang II activate several deleterious pathways that promote inflammation, contributing to inflammatory responses in the body and exacerbating conditions such as seizures. Additionally, the excitatory effect of AT1R by Ang II excess due to ACE2 inhibition by SARS-CoV-2 or by the vaccine Spike protein may play a further role in the mechanism contributing to epilepsy.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fajloun</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Sciences 3, Department of Biology, Lebanese University, Campus Michel Slayman Ras Maska, 1352 Tripoli, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Culture, Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and its Applications, EDST, Lebanese University, 1300 Tripoli, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tajer</LastName><ForeName>Layla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cell Culture, Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotech-nology and its Applications, EDST, Lebanese University, 1300 Tripoli, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacic</LastName><ForeName>Hervé</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, CNRS, INP, Inst Neurophysiopathol, Aix-Marseille University, 13385 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatier</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, CNRS, INP, Inst Neurophysiopathol, Aix-Marseille University, 13385 Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Infect Disord Drug Targets</MedlineTA><NlmUniqueID>101269158</NlmUniqueID><ISSNLinking>1871-5265</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE</Keyword><Keyword MajorTopicYN="N">ACE/Ang II/AT1R axis</Keyword><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">AT1 Rceptor</Keyword><Keyword MajorTopicYN="N">COVOD-19</Keyword><Keyword MajorTopicYN="N">Epilepsy</Keyword><Keyword MajorTopicYN="N">Neurodegenerative Disease</Keyword><Keyword MajorTopicYN="N">Renin-Angiotensin System</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>1970</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39313888</ArticleId><ArticleId IdType="doi">10.2174/0118715265350339240919053408</ArticleId><ArticleId IdType="pii">IDDT-EPUB-143235</ArticleId></ArticleIdList></PubmedData></PubmedArticle>